Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Rebecca Faresjö"'
Autor:
Rebecca Faresjö, Elisabet O. Sjöström, Tiffany Dallas, Magnus M. Berglund, Jonas Eriksson, Dag Sehlin, Stina Syvänen
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
Neurodegenerative diseases such as Alzheimer’s disease (AD) pose substantial challenges to patients and health-care systems, particularly in countries with aging populations. Immunotherapies, including the marketed antibodies lecanemab (Leqembi®)
Externí odkaz:
https://doaj.org/article/041fd12ae7354b68b4c4b27fadafe24b
Publikováno v:
Fluids and Barriers of the CNS, Vol 20, Iss 1, Pp 1-17 (2023)
Abstract Background Transferrin receptor 1 (TfR1) mediated brain delivery of antibodies could become important for increasing the efficacy of emerging immunotherapies in Alzheimer's disease (AD). However, age, dose, binding to TfR1 on blood cells, an
Externí odkaz:
https://doaj.org/article/92dda6cfd072437c9d62de2f9c2a455d
Autor:
Andrés de la Rosa, Nicole G. Metzendorf, Jamie I. Morrison, Rebecca Faresjö, Fadi Rofo, Alex Petrovic, Paul O’Callaghan, Stina Syvänen, Greta Hultqvist
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-17 (2022)
Abstract The blood–brain barrier (BBB) greatly limits the delivery of protein-based drugs into the brain and is a major obstacle for the treatment of brain disorders. Targeting the transferrin receptor (TfR) is a strategy for transporting protein-b
Externí odkaz:
https://doaj.org/article/aa4b075b0c2048ffaa30444b0494af4a
Autor:
Rebecca Faresjö, Gillian Bonvicini, Xiaotian T. Fang, Ximena Aguilar, Dag Sehlin, Stina Syvänen
Publikováno v:
Fluids and Barriers of the CNS, Vol 18, Iss 1, Pp 1-15 (2021)
Abstract Background Transferrin receptor (TfR1) mediated enhanced brain delivery of antibodies have been studied extensively in preclinical settings. However, the brain pharmacokinetics, i.e. brain entry, distribution and elimination are still not fu
Externí odkaz:
https://doaj.org/article/211db83d4d8c4d658f6944fd83ac6f73
Autor:
Gillian Bonvicini, Xiaotian T. Fang, Dag Sehlin, Ximena Aguilar, Stina Syvänen, Rebecca Faresjö
Publikováno v:
Fluids and Barriers of the CNS, Vol 18, Iss 1, Pp 1-15 (2021)
Fluids and Barriers of the CNS
Fluids and Barriers of the CNS
Background Transferrin receptor (TfR1) mediated enhanced brain delivery of antibodies have been studied extensively in preclinical settings. However, the brain pharmacokinetics, i.e. brain entry, distribution and elimination are still not fully under
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa0047630ad43103367e8351ea058cf9
https://doaj.org/article/211db83d4d8c4d658f6944fd83ac6f73
https://doaj.org/article/211db83d4d8c4d658f6944fd83ac6f73
Publikováno v:
Pharmaceutical research. 39(7)
Affibodies targeting amyloid-beta (Aβ) could potentially be used as therapeutic and diagnostic agents in Alzheimer’s disease (AD). Affibodies display suitable characteristics for imaging applications such as high stability and a short biological h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79f02c9d5ee13dfc2e59d9471b0affef
https://pubmed.ncbi.nlm.nih.gov/35538266
https://pubmed.ncbi.nlm.nih.gov/35538266
Autor:
Stina Syvänen, Johanna Rokka, Xiaotian T. Fang, Dag Erlend Olberg, Lars Lannfelt, Jonas Eriksson, Dag Sehlin, Rebecca Faresjö
Publikováno v:
ACS Chemical Neuroscience
Antibodies are attractive as radioligands due to their outstanding specificity and high affinity, but their inability to cross the blood–brain barrier (BBB) limits their use for CNS targets. To enhance brain distribution, amyloid-β (Aβ) antibodie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03d3d115d5220e825a8fabd72c72bec2
https://doi.org/10.1021/acschemneuro.0c00652
https://doi.org/10.1021/acschemneuro.0c00652
Autor:
Stina Syvänen, Silvio R. Meier, Sahar Roshanbin, Mengfei Xiong, Rebecca Faresjö, Tobias Gustavsson, Gillian Bonvicini, Eva Schlein, Ximena Aguilar, Ulrika Julku, Jonas Eriksson, Dag Sehlin
Positron emission tomography (PET), a medical imaging technique allowing for studies of the living human brain, has gained an important role in clinical trials of novel drugs against Alzheimer’s disease (AD). For example, PET data contributed to th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebc643bb4a01e26758bf8e39ac35425e
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-483631
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-483631
Autor:
Stina Syvänen, Johanna Rokka, Dag Erlend Olberg, Xiaotian T. Fang, Dag Sehlin, Gunnar Antoni, Lars Lannfelt, Greta Hultqvist, Rebecca Faresjö, Jonas Eriksson
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 62:S5-S122
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a77990188eb44479d739b2a49fd89c74
https://doi.org/10.1002/jlcr.3724
https://doi.org/10.1002/jlcr.3724
Autor:
'Rebecca Faresjö
Publikováno v:
Gillian Bonvicini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=r3c4b2081b22::54f91402cdd2a9e7065a9a33be93e5ab